Phase I/II Study of Avelumab in Pediatric Cancer Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 148
Summary
- Conditions
- Lymphoma
- Refractory or Relapsed Solid Tumors
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 18 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03451825
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Investigators
- Study Director: Medical Responsible Merck KGaA, Darmstadt, Germany